• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by BioDelivery Sciences International Inc.

    2/24/22 12:05:58 PM ET
    $BDSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDSI alert in real time by email
    SC 13D 1 tm227590d1_sc13d.htm SC 13D

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D. C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.    )*

     

    BIODELIVERY SCIENCES INTERNATIONAL, INC.

     

    (Name of Issuer)

     

    Common Stock, par value $.001

     

    (Title of Class of Securities)

     

    09060J106

     

    (CUSIP Number of Class of Securities)

     

    Alec N. Litowitz

    Magnetar Capital LLC

    1603 Orrington Ave.

    Evanston, Illinois 60201

    (847) 905-4400

     

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

     

    February 14, 2022

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No.  09060J106 SCHEDULE 13D Page 2 of 12

     

    1.

    NAME OF REPORTING PERSON:

     

    Magnetar Financial LLC

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)     ¨

    (b)     x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)       ¨

     

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8. 

    SHARED VOTING POWER

    6,695,999

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH

    10. 

    SHARED DISPOSITIVE POWER

    6,695,999

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,695,999

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES          ¨

     

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.77%

    14.

    TYPE OF REPORTING PERSON

     

    IA; OO

     

     

     

    CUSIP No.  09060J106 SCHEDULE 13D Page 3 of 12

     

    1.

    NAME OF REPORTING PERSON:

     

    Magnetar Capital Partners LP

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)     ¨

    (b)     x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)       ¨

     

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8. 

    SHARED VOTING POWER

    6,695,999

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH

    10. 

    SHARED DISPOSITIVE POWER

    6,695,999

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,695,999

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES       ¨ 

     

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.77%

    14.

    TYPE OF REPORTING PERSON

     

    HC; OO

     

     

      

    CUSIP No.  09060J106 SCHEDULE 13D Page 4 of 12

     

    1.

    NAME OF REPORTING PERSON:

     

    Supernova Management LLC

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP


    (a)     ¨

    (b)     x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)       ¨

     

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8. 

    SHARED VOTING POWER

    6,695,999

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH

    10. 

    SHARED DISPOSITIVE POWER

    6,695,999

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,695,999

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES      ¨

     

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.77%

    14.

    TYPE OF REPORTING PERSON

     

    HC; OO

     

     

     

    CUSIP No.  09060J106 SCHEDULE 13D Page 5 of 12

     

    1.

    NAME OF REPORTING PERSON:

     

    Alec N. Litowitz

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP


    (a)     ¨

    (b)     x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)       ¨

     

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8. 

    SHARED VOTING POWER

    6,695,999

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH

    10. 

    SHARED DISPOSITIVE POWER

    6,695,999

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,695,999

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES      ¨

     

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.77%

    14.

    TYPE OF REPORTING PERSON

     

    HC; IN

     

     

      

     

    SCHEDULE 13D

     

    item  1.security and issuer

     

    This Schedule 13D (this “Statement”) relates to the common stock, $0.001 par value (the “Shares”), of BioDelivery Sciences International, Inc., a company incorporated in Delaware (the “Company”). The principal executive offices of the Company is 4131 ParkLake Ave, Suite 225, Raleigh, NC, 27612.

     

    Item  2.identity and background

     

    (a)           The persons filing this Statement are Magnetar Financial LLC, a Delaware limited liability company (“Magnetar Financial”), Magnetar Capital Partners LP, a Delaware limited partnership (“Magnetar Capital Partners”), Supernova Management LLC, a Delaware limited liability company (“Supernova Management”), and Alec N. Litowitz (“Mr. Litowitz”) (collectively, the “Reporting Persons”).

     

    This Statement relates to Shares held for the accounts of each of (i) Magnetar PRA Master Fund Ltd, a Cayman Islands exempted company (“PRA Master Fund”), (ii) Magnetar Constellation Fund II-PRA LP, a Delaware limited partnership (“Constellation Fund”), and (iii) Magnetar Systematic Multi-Strategy Master Fund Ltd, a Cayman Islands exempted company, (“Systematic Master Fund”), and one Managed Account for the clients of Magnetar Financial (the “Managed Account”), collectively (the “Funds”).

     

    Magnetar Financial is a Securities and Exchange Commission (“SEC”) registered investment adviser under Section 203 of the Investment Advisers Act of 1940, as amended, and manager of investment funds and managed accounts. Magnetar Financial serves as investment adviser to each of the Funds. In such capacity, Magnetar Financial exercises voting and investment power over the Shares held for the accounts of each of the Funds. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Financial. Supernova Management is the general partner of Magnetar Capital Partners. The manager of Supernova Management is Mr. Litowitz.

     

    (b)           The business address of each of the Reporting Persons is 1603 Orrington Avenue, 13th Floor, Evanston, Illinois 60201.

     

    (c)           Each of the Funds is a private investment fund; Magnetar Financial is a privately-held SEC registered investment adviser and manager of investment funds and managed accounts; Magnetar Capital Partners is a privately-held limited partnership and serves as the sole member and parent holding company of Magnetar Financial; Supernova Management is a privately-held limited liability company and is the general partner of Magnetar Capital Partners; and Mr. Litowitz is a citizen of the United States of America, manager of Supernova Management and Chief Executive Officer of Magnetar Financial.

     

    (d)           None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)           None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)            Magnetar Financial is a Delaware limited liability company. Magnetar Capital Partners is a Delaware limited partnership. Supernova Management is a Delaware limited liability company. Mr. Litowitz is a citizen of the United States of America.

     

     

     

     

    Item  3.source and amount of funds or other consideration

     

    The aggregate amount of funds used by the Reporting Persons in purchasing the 6,695,999 Shares reported herein on behalf of the Funds have come directly from the assets of the Funds, which may at any given time, have included margin loans made by brokerage firms in the ordinary course of business. The aggregate amount of funds used by the Reporting Persons in purchasing the Shares on behalf of the Funds was $37,097,900.74 (excluding commissions and other execution-related costs).

     

    ITEM  4.PURPOSE OF TRANSACTION

     

    The Reporting Persons acquired the 6,695,999 Shares reported herein on behalf of the Funds after the public announcement of the Merger Agreement (as defined below) for purposes of receiving the merger consideration described below upon consummation of the Merger (as described below).

     

    Each of the Reporting Persons reserves the right to acquire additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4.

     

    Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.

     

    ITEM  5.INTEREST IN SECURITIES OF THE ISSUER

     

    The Company reported in their Form 10-Q filed on November 13, 2021 that 102,061,623 Shares were issued and 98,795,939 Shares outstanding as of November 3, 2021.

     

    (a)           As of the close of business February 23, 2022, each of the Reporting Persons may have been deemed to have beneficial ownership of 6,695,999 Shares, which consisted of (i) 3,866,322 Shares held for the benefit of PRA Master Fund, (ii) 2,071,023 Shares held for the benefit of Constellation Fund, and (iii) 758,654 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 6.77% of the Shares.

     

    (b)           As of the close of business February 23, 2022, each of the Reporting Persons may have been deemed to share the power to vote and direct the disposition of 6,695,999 Shares, which consisted of (i) 3,866,322 Shares held for the benefit of PRA Master Fund, (ii) 2,071,023 Shares held for the benefit of Constellation Fund, and (iii) 758,654 Shares held for the benefit of Systematic Master Fund and all such Shares represented beneficial ownership of approximately 6.77% of the Shares.

     

     

     

     

    (c)           Except as set forth on Schedule A attached hereto and Item 6, the Funds had no transactions in the Shares during the 60 days preceding the date of filing of this Statement. All of the transactions set forth on Schedule A attached hereto were effected in the ordinary course of business of Magnetar Financial for the accounts of each of the Funds. The transactions in the Shares set forth on Schedule A were effected in open market transactions on the NASDAQ and various other trading markets.

     

    As disclosed by the Company in the 8-K filed with the SEC on February 12, 2022:

     

    On February 14, 2022, BioDelivery Sciences International, Inc., a Delaware corporation (“BDSI”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Collegium Pharmaceutical, Inc., a Virginia corporation (“Collegium”), and Bristol Acquisition Company Inc., a Delaware corporation and wholly owned subsidiary of Collegium (“Purchaser”).

     

    Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, as promptly as practicable (but in no event more than 10 business days after the date of the Merger Agreement), Purchaser will commence a cash tender offer (the “Offer”), to acquire all of the outstanding shares (the “Shares”) of BDSI’s common stock, $0.001 par value per share (the “BDSI Common Stock”), at an offer price of $5.60 per Share in cash, subject to applicable withholding taxes and without interest (the “Offer Price”). The Offer will initially remain open for 20 business days from the date of commencement of the Offer, subject to extension under certain circumstances.

     

    (d)           No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any Shares that are beneficially owned by the Reporting Persons.

     

    Item  6. contracts, arrangements, understandings or relationships with respect to the securities of the issuer

     

    Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, and any amendment or amendments hereto.

     

    Except as otherwise described herein, no contracts, arrangements, understandings or similar relationships exist with respect to the securities of the Company among or between the Reporting Persons or any other person or entity.

     

     

     

     

    ITEM  7.MATERIAL TO BE FILED AS EXHIBITS

     

    Exhibit No. Description

     

    99.1Joint Filing Agreement, dated as of February 24, 2022 among the Reporting Persons.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:   February 24, 2022

     

      magnetar financial llc
       
      By: Magnetar Capital Partners LP, its Sole Member
       
      By: /s/ Alec N. Litowitz
        Name: Alec N. Litowitz
        Title: Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP
       
      magnetar capital partners LP
       
      By: /s/ Alec N. Litowitz
        Name: Alec N. Litowitz
        Title: Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP
       
      supernova management llc
       
      By: /s/ Alec N. Litowitz
        Name: Alec N. Litowitz
        Title: Manager
       
      /s/ Alec N. Litowitz
      Alec N. Litowitz

     

     

     

     

    SCHEDULE A

     

    Funds

     

    Date   Number of Shares Bought   Price Per Share($) (1)(2) 
     12/20/2021    596,526    3.05611 (3) 
     12/31/2021    120,409    3.05928 (4) 
     1/5/2022    25,000    3.10980 (5) 
     1/6/2022    25,000    3.04916 (6) 
     1/10/2022    25,000    3.12491 (7) 
     1/11/2022    40,000    3.08027 (8) 
     1/12/2022    50,000    3.07290 (9) 
     1/14/2022    25,000    3.01988 (10) 
     1/19/2022    25,000    3.01990 (11) 
     2/1/2022    41,420    3.69750 (12) 
     2/7/2022    21,110    3.67627 (13) 
     2/14/2022    5,173,749    5.53661 (14) 
     2/15/2022    1,192,510    5.55052 (15) 
     2/16/2022    329,740    5.56136 (16) 

     

    (1) Excludes commissions and other execution-related costs.

    (2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

    (3) Reflects a weighted average purchase price of $3.05611 per share, at prices ranging from $2.70 to $3.33 per share.

    (4) Reflects a weighted average purchase price of $3.05928 per share, at prices ranging from $3.07 to $3.15 per share.

    (5) Reflects a weighted average purchase price of $3.10980 per share, at prices ranging from $3.11to $3.12 per share.

    (6) Reflects a weighted average purchase price of $3.04916 per share, at prices ranging from $3.04 to $3.06 per share.

    (7) Reflects a weighted average purchase price of $3.12491 per share, at prices ranging from $3.12 to $3.13 per share.

    (8) Reflects a weighted average purchase price of $3.08027 per share, at prices ranging from $3.08 to $3.08 per share.

    (9) Reflects a weighted average purchase price of $3.07290 per share, at prices ranging from $3.05 to $3.09 per share.

    (10) Reflects a weighted average purchase price of $3.01988 per share, at prices ranging from $3.02 to $3.02 per share.

    (11) Reflects a weighted average purchase price of $3.01990 per share, at prices ranging from $3.02 to $3.02 per share.

    (12) Reflects a weighted average purchase price of $3.69750 per share, at prices ranging from $3.55 to $3.76 per share.

    (13) Reflects a weighted average purchase price of $3.67627 per share, at prices ranging from $3.60 to $3.73 per share.

    (14) Reflects a weighted average purchase price of $5.53661 per share, at prices ranging from $5.50 to $5.57 per share.

    (15) Reflects a weighted average purchase price of $5.55052 per share, at prices ranging from $5.54 to $5.56 per share.

    (16) Reflects a weighted average purchase price of $5.56136 per share, at prices ranging from $5.54 to $5.57 per share.

     

    Funds

     

    Date   Number of Shares (Sold)   Price Per Share($) (1)(2) 
     1/21/2022    (75,000)    3.40255 (17) 
     1/24/2022    (50,000)    3.60392 (18) 
     2/14/2022    (2,330,592)    5.55105 (19) 

     

    (17) Reflects a weighted average purchase price of $3.40255 per share, at prices ranging from $3.33 to $3.46 per share.

    (18) Reflects a weighted average purchase price of $3.60392 per share, at prices ranging from $3.57 to $3.72 per share.

    (19) Reflects a weighted average purchase price of $5.51105 per share, at prices ranging from $5.50 to $5.53 per share.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description

     

    99.1  Joint Filing Agreement, dated as of February 24, 2022, among the Reporting Persons.

     

     

     

    Get the next $BDSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDSI

    DatePrice TargetRatingAnalyst
    2/15/2022$5.00 → $5.60Overweight → Neutral
    Piper Sandler
    1/21/2022$4.00 → $4.50Neutral
    HC Wainwright & Co.
    11/4/2021$6.00 → $4.50Buy → Neutral
    HC Wainwright & Co.
    8/5/2021$5.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BDSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genenta Provides First Half 2022 Business Update and Financial Results

      Current dose escalation study data shows a median overall survival of 17 monthsAdding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30, 2022, providing a cash runway until the end of 2024€1.8 million unrealized foreign exchange gain MILAN, Italy and NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), ("Genenta" or the "Company"), a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, provides business and financial results for the six months ended June 30, 2022.

      10/24/22 7:30:00 AM ET
      $GNTA
      $BDSI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Genenta Announces Nomination of Mark A. Sirgo as Chair

      35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair. Stephen Squinto, PhD is stepping down from his role as Chair on May 1, 2022 to pursue a new business opportunity. Dr. Sirgo most recently was CEO of Aruna Bio, Inc., a preclinical biotech compan

      4/27/22 7:30:00 AM ET
      $BDSI
      $GNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Collegium Completes the Acquisition of BDSI

      STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI"). "This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integratio

      3/22/22 5:01:00 PM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by BioDelivery Sciences International Inc. (Amendment)

      SC 13G/A - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/10/23 4:14:56 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by BioDelivery Sciences International Inc.

      SC 13D - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/24/22 12:05:58 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BioDelivery Sciences International Inc.

      SC 13G - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/24/22 11:06:16 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Financials

    Live finance-specific insights

    See more
    • Collegium Completes the Acquisition of BDSI

      STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI"). "This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integratio

      3/22/22 5:01:00 PM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio

      - Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Accelerate Cash Flow Generation - - Addition of BELBUCA® Provides a Second Growth Driver and ELYXYB™ Establishes Foothold in Neurology - - Conference Call Scheduled for Today at 8:30 a.m. ET - STOUGHTON, Mass. and RALEIGH, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash. BDSI has a portfolio of pain and neurology products that addre

      2/14/22 6:30:00 AM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioDelivery Sciences Reports Solid Third Quarter 2021 Results

      Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential long-term peak sales opportunity of $350 - $400 million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported solid financial results for the third quarter ended

      11/3/21 8:00:00 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    SEC Filings

    See more
    • SEC Form 15-12B filed by BioDelivery Sciences International Inc.

      15-12B - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      4/1/22 5:02:37 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by BioDelivery Sciences International Inc.

      EFFECT - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      3/28/22 12:15:08 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by BioDelivery Sciences International Inc.

      S-8 POS - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      3/23/22 5:30:38 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Leadership Updates

    Live Leadership Updates

    See more
    • BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer

      RALEIGH, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial Officer, effective November 4, 2021.  Mr. Golubieski brings to BDSI more than 30 years of financial and operational experience and will serve as a member of the company's executive leadership team. "I'm pleased to welcome John to our executive leadership team. His appointment comes at a time of significant opportunity and growth for BDSI," said Jeff Bailey, Chief Executive Officer. "I know first-h

      10/21/21 8:00:00 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

      BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

      8/16/21 8:00:00 AM ET
      $AZRX
      $BCPC
      $BDSI
      Major Pharmaceuticals
      Health Care
      Major Chemicals
      Industrials

    $BDSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioDelivery Sciences Intl downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded BioDelivery Sciences Intl from Overweight to Neutral and set a new price target of $5.60 from $5.00 previously

      2/15/22 4:35:51 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on BioDelivery Sciences Intl with a new price target

      HC Wainwright & Co. reiterated coverage of BioDelivery Sciences Intl with a rating of Neutral and set a new price target of $4.50 from $4.00 previously

      1/21/22 6:26:41 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioDelivery Sciences Intl downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded BioDelivery Sciences Intl from Buy to Neutral and set a new price target of $4.50 from $6.00 previously

      11/4/21 7:12:11 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Watson W. Mark disposed of 90,663 shares, closing all direct ownership in the company to satisfy tax liability

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:18:46 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vollins James (withholding tax)

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:18:09 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Singh Vanila disposed of 35,851 shares, closing all direct ownership in the company to satisfy withholding tax

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:17:22 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care